Cost-Effectiveness Of Upcoming Diabetes And Asthma Drugs To Get ICER Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
ICER is likely to consider whether Novo Nordisk's Tresiba can be differentiated from other long-acting insulins and the potential size of the patient population for GlaxoSmithKline's asthma drug, Nucala.
You may also be interested in...
Novo Nordisk Dismayed By “Complete Response” Letter For Insulin Degludec
FDA is requesting data from a dedicated cardiovascular outcomes trial before approving the ultra-long-acting insulins Tresiba and Ryzodeg. News of the regulatory setback caused a 13% drop in the company’s stock price on Feb. 11.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.